These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 16190764)
1. Potent cannabinergic indole analogues as radioiodinatable brain imaging agents for the CB1 cannabinoid receptor. Deng H; Gifford AN; Zvonok AM; Cui G; Li X; Fan P; Deschamps JR; Flippen-Anderson JL; Gatley SJ; Makriyannis A J Med Chem; 2005 Oct; 48(20):6386-92. PubMed ID: 16190764 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationship of a novel series of aminoalkylindoles with potential for imaging the neuronal cannabinoid receptor by positron emission tomography. Willis PG; Pavlova OA; Chefer SI; Vaupel DB; Mukhin AG; Horti AG J Med Chem; 2005 Sep; 48(18):5813-22. PubMed ID: 16134948 [TBL] [Abstract][Full Text] [Related]
3. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide. Murineddu G; Ruiu S; Loriga G; Manca I; Lazzari P; Reali R; Pani L; Toma L; Pinna GA J Med Chem; 2005 Nov; 48(23):7351-62. PubMed ID: 16279795 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the in vivo receptor occupancy for the behavioral effects of cannabinoids using a radiolabeled cannabinoid receptor agonist, R-[125/131I]AM2233. Dhawan J; Deng H; Gatley SJ; Makriyannis A; Akinfeleye T; Bruneus M; Dimaio AA; Gifford AN Synapse; 2006 Aug; 60(2):93-101. PubMed ID: 16715483 [TBL] [Abstract][Full Text] [Related]
5. Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. Frost JM; Dart MJ; Tietje KR; Garrison TR; Grayson GK; Daza AV; El-Kouhen OF; Yao BB; Hsieh GC; Pai M; Zhu CZ; Chandran P; Meyer MD J Med Chem; 2010 Jan; 53(1):295-315. PubMed ID: 19921781 [TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands. Song KS; Lee SH; Chun HJ; Kim JY; Jung ME; Ahn K; Kim SU; Kim J; Lee J Bioorg Med Chem; 2008 Apr; 16(7):4035-51. PubMed ID: 18243711 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. Ruiu S; Pinna GA; Marchese G; Mussinu JM; Saba P; Tambaro S; Casti P; Vargiu R; Pani L J Pharmacol Exp Ther; 2003 Jul; 306(1):363-70. PubMed ID: 12663689 [TBL] [Abstract][Full Text] [Related]
8. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Onaivi ES; Ishiguro H; Gong JP; Patel S; Perchuk A; Meozzi PA; Myers L; Mora Z; Tagliaferro P; Gardner E; Brusco A; Akinshola BE; Liu QR; Hope B; Iwasaki S; Arinami T; Teasenfitz L; Uhl GR Ann N Y Acad Sci; 2006 Aug; 1074():514-36. PubMed ID: 17105950 [TBL] [Abstract][Full Text] [Related]
9. Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. Frost JM; Dart MJ; Tietje KR; Garrison TR; Grayson GK; Daza AV; El-Kouhen OF; Miller LN; Li L; Yao BB; Hsieh GC; Pai M; Zhu CZ; Chandran P; Meyer MD J Med Chem; 2008 Mar; 51(6):1904-12. PubMed ID: 18311894 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Chen RZ; Frassetto A; Lao JZ; Huang RR; Xiao JC; Clements MJ; Walsh TF; Hale JJ; Wang J; Tong X; Fong TM Eur J Pharmacol; 2008 Apr; 584(2-3):338-42. PubMed ID: 18336811 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. Muccioli GG; Wouters J; Charlier C; Scriba GK; Pizza T; Di Pace P; De Martino P; Poppitz W; Poupaert JH; Lambert DM J Med Chem; 2006 Feb; 49(3):872-82. PubMed ID: 16451053 [TBL] [Abstract][Full Text] [Related]
12. Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship. Rao GK; Kaminski NE J Pharmacol Exp Ther; 2006 May; 317(2):820-9. PubMed ID: 16436496 [TBL] [Abstract][Full Text] [Related]
13. Structural modifications of the cannabinoid side chain towards C3-aryl and 1',1'-cycloalkyl-1'-cyano cannabinoids. Papahatjis DP; Nahmias VR; Andreou T; Fan P; Makriyannis A Bioorg Med Chem Lett; 2006 Mar; 16(6):1616-20. PubMed ID: 16387492 [TBL] [Abstract][Full Text] [Related]
14. 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. Huffman JW; Szklennik PV; Almond A; Bushell K; Selley DE; He H; Cassidy MP; Wiley JL; Martin BR Bioorg Med Chem Lett; 2005 Sep; 15(18):4110-3. PubMed ID: 16005223 [TBL] [Abstract][Full Text] [Related]
15. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. Khanolkar AD; Lu D; Ibrahim M; Duclos RI; Thakur GA; Malan TP; Porreca F; Veerappan V; Tian X; George C; Parrish DA; Papahatjis DP; Makriyannis A J Med Chem; 2007 Dec; 50(26):6493-500. PubMed ID: 18038967 [TBL] [Abstract][Full Text] [Related]
16. Development of CoMFA and CoMSIA models of affinity and selectivity for indole ligands of cannabinoid CB1 and CB2 receptors. De Freitas GB; da Silva LL; Romeiro NC; Fraga CA Eur J Med Chem; 2009 Jun; 44(6):2482-96. PubMed ID: 19249138 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. Donohue SR; Varnäs K; Jia Z; Gulyás B; Pike VW; Halldin C Bioorg Med Chem Lett; 2009 Nov; 19(21):6209-12. PubMed ID: 19767206 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. Govaerts SJ; Muccioli GG; Hermans E; Lambert DM Eur J Pharmacol; 2004 Jul; 495(1):43-53. PubMed ID: 15219819 [TBL] [Abstract][Full Text] [Related]
19. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. Dziadulewicz EK; Bevan SJ; Brain CT; Coote PR; Culshaw AJ; Davis AJ; Edwards LJ; Fisher AJ; Fox AJ; Gentry C; Groarke A; Hart TW; Huber W; James IF; Kesingland A; La Vecchia L; Loong Y; Lyothier I; McNair K; O'Farrell C; Peacock M; Portmann R; Schopfer U; Yaqoob M; Zadrobilek J J Med Chem; 2007 Aug; 50(16):3851-6. PubMed ID: 17630726 [TBL] [Abstract][Full Text] [Related]
20. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]